171 related articles for article (PubMed ID: 8771368)
1. Thymic humoral factor-gamma 2 (THF-gamma 2) immunotherapy reduces the metastatic load and restores immunocompetence in 3LL tumor-bearing mice receiving anticancer chemotherapy.
Ophir R; Pecht M; Keisari Y; Rashid G; Lourie S; Meshorer A; Ben-Efraim S; Trainin N; Burstein Y
Immunopharmacol Immunotoxicol; 1996 May; 18(2):209-36. PubMed ID: 8771368
[TBL] [Abstract][Full Text] [Related]
2. Inhibition of murine Lewis lung carcinoma metastases by combined chemotherapy and intranasal THF-gamma 2 immunotherapy.
Rashid G; Ophir R; Pecht M; Lourie S; Meshorer A; Ben-Efraim S; Trainin N; Burstein Y; Keisari Y
J Immunother Emphasis Tumor Immunol; 1996 Sep; 19(5):324-33. PubMed ID: 8941872
[TBL] [Abstract][Full Text] [Related]
3. Cancer immunotherapy with interleukin 12 and granulocyte-macrophage colony-stimulating factor-encapsulated microspheres: coinduction of innate and adaptive antitumor immunity and cure of disseminated disease.
Hill HC; Conway TF; Sabel MS; Jong YS; Mathiowitz E; Bankert RB; Egilmez NK
Cancer Res; 2002 Dec; 62(24):7254-63. PubMed ID: 12499267
[TBL] [Abstract][Full Text] [Related]
4. Treating tumor-bearing mice with low-dose gamma-interferon plus tumor necrosis factor alpha to diminish immune suppressive granulocyte-macrophage progenitor cells increases responsiveness to interleukin 2 immunotherapy.
Pak AS; Ip G; Wright MA; Young MR
Cancer Res; 1995 Feb; 55(4):885-90. PubMed ID: 7850804
[TBL] [Abstract][Full Text] [Related]
5. Vascular endothelial growth factor blockade reduces intratumoral regulatory T cells and enhances the efficacy of a GM-CSF-secreting cancer immunotherapy.
Li B; Lalani AS; Harding TC; Luan B; Koprivnikar K; Huan Tu G; Prell R; VanRoey MJ; Simmons AD; Jooss K
Clin Cancer Res; 2006 Nov; 12(22):6808-16. PubMed ID: 17121902
[TBL] [Abstract][Full Text] [Related]
6. Potentiation of myeloid colony-formation in bone marrow of intact and neonatally thymectomized mice by the thymic hormone THF-gamma 2.
Pecht M; Lourie S; Burstein Y; Zipori D; Trainin N
Exp Hematol; 1993 Feb; 21(2):277-82. PubMed ID: 8425564
[TBL] [Abstract][Full Text] [Related]
7. Anti-programmed death-1 synergizes with granulocyte macrophage colony-stimulating factor--secreting tumor cell immunotherapy providing therapeutic benefit to mice with established tumors.
Li B; VanRoey M; Wang C; Chen TH; Korman A; Jooss K
Clin Cancer Res; 2009 Mar; 15(5):1623-34. PubMed ID: 19208793
[TBL] [Abstract][Full Text] [Related]
8. Myelopoiesis-associated immune suppressor cells in mice bearing metastatic Lewis lung carcinoma tumors: gamma interferon plus tumor necrosis factor alpha synergistically reduces immune suppressor and tumor growth-promoting activities of bone marrow cells and diminishes tumor recurrence and metastasis.
Young MR; Wright MA
Cancer Res; 1992 Nov; 52(22):6335-40. PubMed ID: 1423279
[TBL] [Abstract][Full Text] [Related]
9. Thymic humoral factor-gamma 2 augments immune cell response and exerts antitumor activity in murine model systems.
Beuth J; Schierholz JM; Mayer G; Keisari Y
Anticancer Res; 2000; 20(6B):4473-6. PubMed ID: 11205290
[TBL] [Abstract][Full Text] [Related]
10. Development of resistance to MOPC-315 plasmacytoma after intralesional and intraperitoneal melphalan therapy of tumor-bearing BALB/c mice. I. Enhancement of in vivo rejection responses by combined chemotherapy-immunotherapy.
Adler A; Altbaum I
J Natl Cancer Inst; 1982 Jun; 68(6):963-9. PubMed ID: 6953275
[TBL] [Abstract][Full Text] [Related]
11. Combinational FLt3 ligand and granulocyte macrophage colony-stimulating factor treatment promotes enhanced tumor infiltration by dendritic cells and antitumor CD8(+) T-cell cross-priming but is ineffective as a therapy.
Berhanu A; Huang J; Alber SM; Watkins SC; Storkus WJ
Cancer Res; 2006 May; 66(9):4895-903. PubMed ID: 16651446
[TBL] [Abstract][Full Text] [Related]
12. THF-gamma 2-mediated reduction of pulmonary metastases and augmentation of immunocompetence in C57BL/6 mice bearing B16-melanoma.
Ophir R; Moalem G; Pecht M; Shashoua M; Rashid G; Ben-Efraim S; Trainin N; Burstein Y; Keisari Y
J Immunother; 1999 Mar; 22(2):103-13. PubMed ID: 10093035
[TBL] [Abstract][Full Text] [Related]
13. Importance of cyclophosphamide-induced bystander effect on T cells for a successful tumor eradication in response to adoptive immunotherapy in mice.
Proietti E; Greco G; Garrone B; Baccarini S; Mauri C; Venditti M; Carlei D; Belardelli F
J Clin Invest; 1998 Jan; 101(2):429-41. PubMed ID: 9435316
[TBL] [Abstract][Full Text] [Related]
14. Enhancement of the anti-tumor efficacy of a GM-CSF-secreting tumor cell immunotherapy in preclinical models by cytosine arabinoside.
Lin JM; Li B; Rimmer E; VanRoey M; Jooss K
Exp Hematol; 2008 Mar; 36(3):319-28. PubMed ID: 18279719
[TBL] [Abstract][Full Text] [Related]
15. Augmenting major histocompatibility complex class I expression by murine tumors in vivo enhances antitumor immunity induced by an active immunotherapy strategy.
Merritt RE; Yamada RE; Crystal RG; Korst RJ
J Thorac Cardiovasc Surg; 2004 Feb; 127(2):355-64. PubMed ID: 14762342
[TBL] [Abstract][Full Text] [Related]
16. Cyclophosphamide enhances the antitumor efficacy of adoptively transferred immune cells through the induction of cytokine expression, B-cell and T-cell homeostatic proliferation, and specific tumor infiltration.
Bracci L; Moschella F; Sestili P; La Sorsa V; Valentini M; Canini I; Baccarini S; Maccari S; Ramoni C; Belardelli F; Proietti E
Clin Cancer Res; 2007 Jan; 13(2 Pt 1):644-53. PubMed ID: 17255288
[TBL] [Abstract][Full Text] [Related]
17. Successful adoptive cellular immunotherapy is dependent on induction of a host immune response triggered by cytokine (IFN-gamma and granulocyte/macrophage colony-stimulating factor) producing donor tumor-infiltrating lymphocytes.
Nagoshi M; Goedegebuure PS; Burger UL; Sadanaga N; Chang MP; Eberlein TJ
J Immunol; 1998 Jan; 160(1):334-44. PubMed ID: 9551989
[TBL] [Abstract][Full Text] [Related]
18. Thymic humoral factor-gamma 2, an immunoregulatory peptide, enhances human hematopoietic progenitor cell growth.
Barak Y; Hahn T; Pecht M; Karov Y; Berrebi A; Zaizov R; Stark B; Buchner V; Burstein Y; Trainin N
Exp Hematol; 1992 Feb; 20(2):173-7. PubMed ID: 1544385
[TBL] [Abstract][Full Text] [Related]
19. Vascular attack by 5,6-dimethylxanthenone-4-acetic acid combined with B7.1 (CD80)-mediated immunotherapy overcomes immune resistance and leads to the eradication of large tumors and multiple tumor foci.
Kanwar JR; Kanwar RK; Pandey S; Ching LM; Krissansen GW
Cancer Res; 2001 Mar; 61(5):1948-56. PubMed ID: 11280751
[TBL] [Abstract][Full Text] [Related]
20. The effect of recombinant murine interferon-gamma on the hematopoietic and immunological parameters of mice bearing metastatic Lewis lung carcinoma tumors.
Young MR; Young ME; Wepsic HT
Exp Hematol; 1988 May; 16(4):295-301. PubMed ID: 2966070
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
